Skip to main content

Refine your results

Filters
Search
Include spaces in matter number if applicable. Ex.: 182 3125
Date
Displaying 30441 - 30460 of 44836
Early Termination Notices

20021129: Edward W. Stack; Edward W. Stack

… 20021129: Edward W. Stack; Edward W. Stack HSR Early Termination Notice 20021129: Edward W. Stack; Edward W. Stack 20021129 Dick's Sporting Goods, Inc. Edward W. Stack Edward W. Stack … 20021129: Edward W. …
Date
Acquiring Party
Edward W. Stack
Acquired Party
Edward W. Stack
Acquired Entities
Dick's Sporting Goods, Inc.
Early Termination Notices

20021128: Scottish Power plc; Aquila, Inc.

… 20021128: Scottish Power plc; Aquila, Inc. HSR Early Termination Notice 20021128: Scottish Power plc; Aquila, Inc. 20021128 Aquila Merchant Services, Inc. Aquila Storage …
Date
Acquiring Party
Scottish Power plc
Acquired Party
Aquila, Inc.
Acquired Entities
Aquila Merchant Services, Inc.
Aquila Storage and Transportation, L.P.
Early Termination Notices

20021101: William H. Gates, III; Six Flags, Inc.

… 20021101: William H. Gates, III; Six Flags, Inc. HSR Early Termination Notice 20021101: William H. Gates, III; Six Flags, Inc. 20021101 Six Flags, Inc. Six Flags, Inc. William H. …
Date
Acquiring Party
William H. Gates, III
Acquired Party
Six Flags, Inc.
Acquired Entities
Six Flags, Inc.
Federal Register Notice

Conoco Inc. And Phillips Petroleum Company; Analysis to Aid Public Comment

… Conoco Inc. And Phillips Petroleum Company; Analysis to Aid Public Comment Federal Register Notice Conoco Inc. And Phillips Petroleum Company; Analysis to Aid Public Comment 021 0040 020909conocoincphillipspetroleum.pdf … Conoco Inc. And Phillips …
Date
Cases and Proceedings

Amgen Inc. and Immunex Corporation

… Amgen Inc. and Immunex Corporation Amgen Inc. and Immunex Corporation Amgen settled antitrust charges … would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood …

Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and interleukin-1 (IL-1) inhibitors. The consent order requires the firms to sell all of Immunex's assets related to Leukine -a neutrophil regeneration factor -to Schering AG; license certain intellectual property rights to TNF inhibitors to Serono S.A.; and license certain intellectual property rights related to IL-1 inhibitors to Regeneron Pharmaceuticals Inc.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0210059
Docket Number
C-4056
Displaying 30441 - 30460 of 44836
Return to top